Citations

Clear

846 citation(s) found for "Li, Min".

Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer
McCall, Linda, Yi, Min , Hansen, Nora , Gabram, Sheryl G. A., Hurd, Thelma C. , Giuliano, Armando E. , Mittendorf, Elizabeth A, McCall, Linda M, Şahin, Ayşegül A. , Bedrosian, Isabelle , Gabram, Sheryl, Hurd, Thelma, Hunt, Kelly K. , Mittendorf, EA , Ballman, Karla V.

Mayo Clinic

Journal of Clinical Oncology | December 9, 2014 | Volume: 33 | Issue: 10 | Pages: 1119-1127

10.1200/jco.2014.57.2958 | PMID 25488970 Get It

Purpose The seventh edition of the American Joint Committee on Cancer (AJCC) staging system for breast cancer differentiates patients with T1 tumors and lymph node micrometastases (stage IB) from patients with T1 tumors and negative nodes (stage IA). This study was undertaken to determine the utility of the stage IB designation. Patients and Methods The following two cohorts of patients with breast cancer were identified: 3,474 patients treated at The University of Texas MD Anderson Cancer Center from 1993 to 2007 and 4,590 patients from the American College of Surgeons Oncology Group (ACOSOG) Z0010 trial. Clinicopathologic and outcomes data were recorded, and disease was staged according to the seventh edition AJCC staging system. Recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS) were determined using the Kaplan-Meier method and compared using the log-rank test. Results Median follow-up times were 6.1 years and 9.0 years for the MD Anderson Cancer Center and ACOSOG cohorts, respectively. In both cohorts, there were no significant differences between patients with stage IA and stage IB disease in 5- or 10-year RFS, DSS, or OS. Estrogen receptor (ER) status and grade significantly stratified patients with stage I disease with respect to RFS, DSS, and OS. Conclusion Among patients with T1 breast cancer, individuals with micrometastases and those with negative nodes have similar survival outcomes. ER status and grade are better discriminants of survival than the presence of small-volume nodal metastases. In preparing the next edition of the AJCC staging system, consideration should be given to eliminating the stage IB designation and incorporating biologic factors.
A preoperative serum signature of CEA+/CA125+/CA19‐9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer
Xu, Huaxiang , Wu, Chuntao , Yang, Jingxuan , Cen, Putao , Xu, Jin , Liu, Chen , Long, Jiang , Guha, Sushovan , Ni, Quanxing, Jatoi, Aminah , Chari, Suresh T. , McCleary‐Wheeler, Angela L. , Fernández-Zapico, Martín E. , Yu, Xianjun , Liu, Liang , Wang, Wenquan , Chen, Yong , Fu, Deliang , Li, Min , Yang, Jingxuan , Chari, Suresh T

Mayo Clinic

International Journal of Cancer | October 1, 2014 | Volume: 136 | Issue: 9 | Pages: 2216-2227

10.1002/ijc.29242 | PMID 25273947 Get It

Pancreatectomy is associated with significant morbidity and unpredictable outcome, with few diagnostic tools to determine, which patients gain the most benefit from this treatment, especially before the operation. This study aimed to define a preoperative signature panel of serum markers to indicate response to pancreatectomy for pancreatic cancer. Over 1000 patients with pancreatic cancer treated at two independent high‐volume institutions were included in this study and were divided into three groups, including resected, locally advanced and metastatic. Eight serum tumor markers most commonly used in gastrointestinal cancers were analyzed for patient outcome. Preoperative CA19‐9 independently indicated surgical response in pancreatic cancer. Patients with CA19‐9 ≥1000 U/mL generally had a poor surgical benefit. However, a subset of these patients still achieved a survival advantage when CA19‐9 levels decreased postoperatively. CEA and CA125 in the presence of CA19‐9 ≥1000 U/mL could independently predict the non‐decrease of CA19‐9 postoperatively. The combination of the three markers was useful for predicting a worse surgical outcome with a median survival of 5.1 months vs. 23.0 months (p < 0.001) for the training cohort and 7.0 months vs. 18.2 months (p < 0.001) for the validation cohort and also suggested a higher prevalence of early distant metastasis after surgery. Resected patients with this proposed signature showed no survival advantage over patients in the locally advanced group who did not receive pancreatectomy. Therefore, a preoperative serum signature of CEA+/CA125+/CA19‐9 ≥1000 U/mL is associated with poor surgical outcome and can be used to select appropriate patients with pancreatic cancer for pancreatectomy.
Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma
Mansour, Ahmad M. , Arévalo, J. Fernando , Kahtani, Eman Al, Zegarra, Hernando, Abboud, Emad B. , Anand, Rajiv, Ahmadieh, Hamid , Mirza, Salman, Tuncer, Samuray , Návea, Amparo , Mataix, J. , Ascaso, Francisco J., Pulido, José S. , Guthoff, Rainer , Goebel, Winfried, Banker, Alay , Gentile, Ronald C., Martinez, Isabel Alonso, Morris, Rodney J, Panday, Neeraj, Min, Park Jung, Mercé, Emilie, Lai, Timothy Y. Y. , Massoud, Vicky, Ghazi, Nicola G. , Abboud, Emad , Sisk, Robert A. , Roh, Young‐Jung , Martínez, Isabel Alonso, Massoud, Vicky A., Arevalo, Jose Fernando

Mayo Clinic

Journal of Ophthalmology | July 23, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-8

10.1155/2014/210458 | PMID 25147732 Get It

We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n=15;P=0.001), 105.3 microns at 1 year (n=10;P=0.03), and 157.6 microns at 2 years (n=7;P=0.08). BCVA improved by 3.3 lines at 6 months after therapy (n=26;P<0.001), 2.8 lines (n=20;P=0.01) at 1 year, and 3.1 lines (n=13;P=0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.
Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality
Xu, Hua , Aldrich, Melinda C. , Peterson, Neeraja B. , Levy, Mia , Shah, Anushi, Han, Xue, Ruan, Xiaoyang , Jiang, Min , Li, Ying , Julien, Jamii St., Friedman, Carol, Roden, Dan M. , Denny, Joshua C. , Chen, Qingxia , Liu, Hongfang , Dai, Qi , Han, Xue, Warner, Jeremy L. , Roden, Dan M. , Denny, Joshua C

Mayo Clinic

Journal of the American Medical Informatics Association | July 23, 2014 | Volume: 22 | Issue: 1 | Pages: 179-191

10.1136/amiajnl-2014-002649 | PMID 25053577 Get It

Abstract Objectives Drug repurposing, which finds new indications for existing drugs, has received great attention recently. The goal of our work is to assess the feasibility of using electronic health records (EHRs) and automated informatics methods to efficiently validate a recent drug repurposing association of metformin with reduced cancer mortality. Methods By linking two large EHRs from Vanderbilt University Medical Center and Mayo Clinic to their tumor registries, we constructed a cohort including 32 415 adults with a cancer diagnosis at Vanderbilt and 79 258 cancer patients at Mayo from 1995 to 2010. Using automated informatics methods, we further identified type 2 diabetes patients within the cancer cohort and determined their drug exposure information, as well as other covariates such as smoking status. We then estimated HRs for all-cause mortality and their associated 95% CIs using stratified Cox proportional hazard models. HRs were estimated according to metformin exposure, adjusted for age at diagnosis, sex, race, body mass index, tobacco use, insulin use, cancer type, and non-cancer Charlson comorbidity index. Results Among all Vanderbilt cancer patients, metformin was associated with a 22% decrease in overall mortality compared to other oral hypoglycemic medications (HR 0.78; 95% CI 0.69 to 0.88) and with a 39% decrease compared to type 2 diabetes patients on insulin only (HR 0.61; 95% CI 0.50 to 0.73). Diabetic patients on metformin also had a 23% improved survival compared with non-diabetic patients (HR 0.77; 95% CI 0.71 to 0.85). These associations were replicated using the Mayo Clinic EHR data. Many site-specific cancers including breast, colorectal, lung, and prostate demonstrated reduced mortality with metformin use in at least one EHR. Conclusions EHR data suggested that the use of metformin was associated with decreased mortality after a cancer diagnosis compared with diabetic and non-diabetic cancer patients not on metformin, indicating its potential as a chemotherapeutic regimen. This study serves as a model for robust and inexpensive validation studies for drug repurposing signals using EHR data.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
Kumar, Shaji , Bensinger, William, Zimmerman, Todd M., Reeder, Craig B. , Berg, Deborah, Hui, Ai-Min, Gupta, Neeraj , Bacco, Alessandra Di , Jiang, Yu , Shou, Yaping, Niesvizky, Rubén, Berenson, James R. , Gupta, Neeraj

Mayo Clinic

Blood | June 6, 2014 | Volume: 124 | Issue: 7 | Pages: 1047-1055

10.1182/blood-2014-01-548941 | PMID 24904120 Get It

Key Points Weekly oral proteasome inhibitor ixazomib appears generally well tolerated with manageable toxicity, limited grade 1/2 neuropathy. Data show that more than 25% of 30 evaluable relapsed/refractory myeloma patients who received the MTD had clinically meaningful responses.
Cutting Edge: NK Cells Mediate IgG1-Dependent Hyperacute Rejection of Xenografts
Yin, Dengping , Zeng, Huasong , Ma, Lianli, Shen, Jikun, Byrne, Guerard W. , Xu, Hui Min , Chong, Anita S.

Mayo Clinic

The Journal of Immunology | April 22, 2014 | Volume: 172 | Issue: 12 | Pages: 7235-7238

10.4049/jimmunol.172.12.7235 | PMID 15187097 Get It

Abstract Classic hyperacute rejection is dependent on the activation of the terminal components of complement. Recently, xenoantibodies with limited abilities to activate the classical pathway of complement in vitro have been implicated in the acute vascular rejection of xenografts. It is unclear how these Abs affect their pathogenic activities in vivo. In this study, we demonstrate the ability of an anti-Gal-α1,3Gal (Gal) IgG1, with modest complement-activating abilities in vitro, to induce xenograft rejection. This rejection was dependent on the activation of complement, on FcγR-mediated interactions, and on the presence of NK cells. Inhibition of any one of these factors resulted in the abrogation of IgG1-mediated rejection. In contrast, an anti-Gal IgG3 mAb induced classic, hyperacute rejection that was solely dependent on complement activation. Our observations implicate two types of IgG-mediated rejection; one that is dependent on complement activation, and a second that is uniquely dependent on complement, FcγR, and NK cells.
The Critical Role of LIGHT, a TNF Family Member, in T Cell Development
Lo, James C. , Wu, Qiang , Wang, Yang , Foster, Amy, Roca, Karin, Chen, Min , Tamada, Koji , Wang, Chyung‐Ru , Wang, Jing , Chun, Taehoon , Chen, Lieping , Fu, Yang‐Xin

Mayo Clinic

The Journal of Immunology | April 20, 2014 | Volume: 167 | Issue: 9 | Pages: 5099-5105

10.4049/jimmunol.167.9.5099 | PMID 11673520 Get It

Abstract Negative selection refers to the selective deletion of autoreactive thymocytes but its molecular events have not been well defined. In this study, we demonstrate that a cellular ligand for herpes virus entry mediator and lymphotoxin receptor (LIGHT), a newly identified member of the TNF superfamily, may play a critical role in negative selection. Using TCR transgenic mice, we find that the blockade of LIGHT signaling in vitro and in vivo prevents negative selection induced by peptide and intrathymically expressed Ags, resulting in the rescue of thymocytes from apoptosis. Furthermore, the thymi of LIGHT transgenic mice show severe atrophy with remarkably reduced CD4+CD8+ double-positive cells caused by increased apoptosis, suggesting that LIGHT can delete immature T cells in vivo. Taken together, these results demonstrate a critical role of LIGHT in thymic negative selection of the T cell repertoire.
NBCe1A dimer assemble visualized by bimolecular fluorescence complementation
Chang, Min‐Hwang , Romero, Michael F. , Chen, An‐Ping , Romero, Michael F

Mayo Clinic

American Journal of Physiology-Renal Physiology | January 30, 2014 | Volume: 306 | Issue: 6 | Pages: F672-F680

10.1152/ajprenal.00284.2013 | PMID 24477681 Get It

Mutations in the electrogenic Na+/HCO3−cotransporter (NBCe1) that cause proximal renal tubular acidosis (pRTA), glaucoma, and cataracts in patients are recessive. Parents and siblings of these affected individuals seem asymptomatic although their tissues should make some mutant NBCe1 protein. Biochemical studies with AE1 and NBCe1 indicate that both, and probably all, Slc4 members form dimers. However, the physiologic implications of dimerization have not yet been fully explored. Here, human NBCe1A dimerization is demonstrated by biomolecular fluorescence complementation (BiFC). An enhanced yellow fluorescent protein (EYFP) fragment (1–158, EYFPN) or (159–238, EYFPC) was fused to the NH2or COOH terminus of NBCe1A and mix-and-matched expressed in Xenopus oocyte. The EYFP fluorescent signal was observed only when both EYFP fragments are fused to the NH2terminus of NBCe1A (EYFPN-N-NBCe1A w/ EYFPC-N-NBCe1A), and the electrophysiology data demonstrated this EYFP-NBCe1A coexpressed pair have wild-type transport function. These data suggest NBCe1A forms dimers and that NH2termini from the two monomers are in close proximity, likely pair up, to form a functional unit. To explore the physiologic significance of NBCe1 dimerization, we chose two severe NBCe1 mutations (6.6 and 20% wild-type function individually): S427L (naturally occurring) and E91R (for NH2-terminal structure studies). When we coexpressed S427L and E91R, we measured 50% wild-type function, which can only occur if the S427L-E91R heterodimer is the functional unit. We hypothesize that the dominant negative effect of heterozygous NBCe1 carrier should be obvious if the mutated residues are structurally crucial to the dimer formation. The S427L-E91R heterodimer complex allows the monomers to structurally complement each other resulting in a dimer with wild-type like function.
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Richardson, Paul G. , Vij, Ravi , Chen, Christine , Jakubowiak, Andrzej , Song, Kevin , Belch, Andrew , Shustik, Chaim, Lentzsch, Suzanne , Lacy, Martha Q. , Matous, Jeffrey, Vesole, David H. , Chen, Min , Zaki, Mohamed H. , Jacques, Christian , Yu, Zhinuan, Richardson, Paul Gerard Guy , Siegel, David S. , Hofmeister, Craig C. , Baz, Rachid , Jagannath, Sundar , Lonial, Sagar , Bahlis, Nizar Jacques , Raje, Noopur , Mıkhael, Joseph , Anderson, Kenneth C.

Mayo Clinic

Blood | January 13, 2014 | Volume: 123 | Issue: 12 | Pages: 1826-1832

10.1182/blood-2013-11-538835 | PMID 24421329 Get It

Key Points Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.
Prevalence of Primary Aldosteronism among Asian Hypertensive Patients in Singapore1
Loh, Keh‐Chuan, Koay, Evelyn S. C., Khaw, Min-Cheh, Emmanuel, Shanta, Khaw, Min-Cheh, Young, William F.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 8, 2014 | Volume: 85 | Issue: 8 | Pages: 2854-2859

10.1210/jcem.85.8.6752 | PMID 10946893 Get It